EWA
NBIX icon

EverSource Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

EverSource Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$529K Sell
3,136
-1,421
-31% -$211K 0.02% 545
2026
Q1 		$600K Buy
4,557
+202
+5% +$26.8K 0.02% 528
2025
Q4 		$618K Buy
4,355
+670
+18% +$97.1K 0.02% 470
2025
Q3 		$517K Buy
3,685
+1,899
+106% +$257K 0.02% 492
2025
Q2 		$224K Buy
1,786
+1,441
+418% +$165K 0.01% 811
2025
Q1 		$38.2K Sell
345
-121
-26% -$15.3K ﹤0.01% 1372
2024
Q4 		$63.6K Buy
466
+241
+107% +$29.8K ﹤0.01% 1080
2024
Q3 		$25.9K Buy
225
+49
+28% +$6.72K ﹤0.01% 1354
2024
Q2 		$24.9K Buy
176
+32
+22% +$4.39K ﹤0.01% 1397
2024
Q1 		$19.8K Buy
144
+22
+18% +$3K ﹤0.01% 1365
2023
Q4 		$16.1K Buy
122
+1
+0.8% +$115 ﹤0.01% 1340
2023
Q3 		$13.6K Buy
121
+37
+44% +$3.9K ﹤0.01% 1278
2023
Q2 		$7.92K Buy
84
+79
+1,580% +$7.72K ﹤0.01% 1553
2023
Q1 		$506 Buy
+5
New +$520 ﹤0.01% 2223

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

EverSource Wealth Advisors's NBIX Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Neurocrine Biosciences (NBIX) stake by 31% in Q2 2026, selling an estimated $211K and leaving 3,136 shares worth $529K. The position accounts for 0.02% of the portfolio, ranked #545.

EverSource Wealth Advisors first reported a position in NBIX in Q1 2023 and has held it in 14 quarters since. The position peaked at $618K in Q4 2025. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • EverSource Wealth Advisors held 3,136 shares of Neurocrine Biosciences worth $529K as of Q2 2026.
  • EverSource Wealth Advisors sold 1,421 Neurocrine Biosciences shares in Q2 2026, an estimated $211K.
  • Neurocrine Biosciences made up 0.02% of EverSource Wealth Advisors's portfolio in Q2 2026, its #545 holding.
  • EverSource Wealth Advisors first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 14 quarters since.
  • EverSource Wealth Advisors's Neurocrine Biosciences position peaked at $618K in Q4 2025.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.